Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities

Clinical Rheumatology

Volumn 32, Issue 10, 2013, Pages 1501-1510

  Xu, Xue ^a   Wu, Wen Yu ^a   Tu, Wen Zheng ^b   Chu, Hai Yan ^c   Zhu, Xiao Xia ^a   Liang, Min Rui ^a   Xue, Yu ^a   Wang, Jiu Cun ^c   Zou, He Jian ^a  

^a FUDAN UNIVERSITY   (China)

^b Integrated Hospital   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

RAGE; S100A8; S100A9; Systemic sclerosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALGRANULIN A; CALGRANULIN B; MESSENGER RNA;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; CALGRANULIN A; CALGRANULIN B; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; LUNG; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC; SKIN DISEASES;

EID: 84885331524     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2305-4     Document Type: Article

References (31)

1. Yamamoto T (2009) Scleroderma - pathophysiology. Eur J Dermatol: EJD 19(1):14-24. doi: 10.1684/ejd.2008.0570
2. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573-1576
3. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, Mayes MD, Reveille JD, Agarwal SK (2009) Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 11(5):R147. doi: 10.1186/ar2821
4. Foell D, Frosch M, Sorg C, Roth J (2004) Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta Int J Clin Chem 344(1-2):37-51. doi: 10.1016/j.cccn.2004.02.023
5. Foell D, Wittkowski H, Vogl T, Roth J (2007) S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81(1):28-37. doi: 10.1189/jlb.0306170
6. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86(3):557-566. doi: 10.1189/jlb.1008647
7. Perera C, McNeil HP, Geczy CL (2010) S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol 88(1):41-49. doi: 10.1038/icb.2009.88
8. Soyfoo MS, Roth J, Vogl T, Pochet R, Decaux G (2009) Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol 36(10):2190-2194. doi: 10.3899/jrheum.081302
9. Foell D, Hernandez-Rodriguez J, Sanchez M, Vogl T, Cid MC, Roth J (2004) Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J Pathol 204(3):311-316. doi: 10.1002/path.1660
10. Frosch M, Roth J (2008) New insights in systemic juvenile idiopathic arthritis - from pathophysiology to treatment. Rheumatology (Oxford) 47(2):121-125. doi: 10.1093/rheumatology/kem271
11. Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, Ehrchen J, Heidemann J, Borody T, Roth J, Clancy R (2008) Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 216(2):183-192. doi: 10.1002/path.2394
12. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC Jr (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45(6):694-702. doi: 10.1093/rheumatology/kei244
13. Giusti L, Bazzichi L, Baldini C, Ciregia F, Mascia G, Giannaccini G, Del Rosso M, Bombardieri S, Lucacchini A (2007) Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. J Rheumatol 34(10):2063-2069
14. Fietta A, Bardoni A, Salvini R, Passadore I, Morosini M, Cavagna L, Codullo V, Pozzi E, Meloni F, Montecucco C (2006) Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res Ther 8(6):R160. doi: 10.1186/ar2067
15. Bargagli E, Olivieri C, Prasse A, Bianchi N, Magi B, Cianti R, Bini L, Rottoli P (2008) Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Inflammation 31(5):351-354. doi: 10.1007/s10753-008-9085-z
16. Kumar RK, Harrison CA, Cornish CJ, Kocher M, Geczy CL (1998) Immunodetection of the murine chemotactic protein CP-10 in bleomycin-induced pulmonary injury. Pathology 30(1):51-56
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581-590
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202-205
19. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman AJ, Allegar N, Varga J, Massa M, et al. (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20(11):1892-1896
20. Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 37(3):391-394
21. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117(3):524-529. doi: 10.1172/JCI31487
22. Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5(2):80-93
23. Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M, Cleland L, Roberts-Thomson PJ (2003) Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 33(5-6):216-220
24. Denton CP, Black CM (2004) Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 18(3):271-290. doi: 10.1016/j.berh.2004. 03.001
25. Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11):2437-2444. doi: 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U
26. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A (2003) The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 42(4):534-540
27. Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD (1998) Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 114(2):293-300
28. Hussein MR, Hassan HI, Hofny ER, Elkholy M, Fatehy NA, Abd Elmoniem AE, Ezz El-Din AM, Afifi OA, Rashed HG (2005) Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 58(2):178-184. doi: 10.1136/jcp.2004.019224
29. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S (2009) Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 29(2):180-189. doi: 10.1007/s10875-008-9252-x
30. He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, Yamaya M (2007) The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 293(6):L1427-L1436. doi: 10.1152/ajplung.00075.2007
31. Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M (2006) The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Modern pathology. An Off J US Can Acad Pathol Inc 19(11):1437-1445. doi: 10.1038/modpathol.3800661